Bio-Path Holdings (BPTH)
(Delayed Data from NSDQ)
$2.14 USD
-0.20 (-8.55%)
Updated May 17, 2024 04:00 PM ET
After-Market: $2.18 +0.04 (1.87%) 7:58 PM ET
2-Buy of 5 2
F Value B Growth A Momentum C VGM
Brokerage Reports
Bio-Path Holdings, Inc. [BPTH]
Reports for Purchase
Showing records 21 - 40 ( 118 total )
Company: Bio-Path Holdings, Inc.
Industry: Medical - Drugs
Company: Bio-Path Holdings, Inc.
Industry: Medical - Drugs
Company: Bio-Path Holdings, Inc.
Industry: Medical - Drugs
Phase 1/1b AML Trial of BP1002 Starts Patient Dosing; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: Bio-Path Holdings, Inc.
Industry: Medical - Drugs
Company: Bio-Path Holdings, Inc.
Industry: Medical - Drugs
Company: Bio-Path Holdings, Inc.
Industry: Medical - Drugs
2Q22: Expecting Clinical Newsflow to Pick Up, Funded Into 2H23
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Bio-Path Holdings, Inc.
Industry: Medical - Drugs
1Q22 Financial Results Reported; Reiterate Buy; Modulating PT to $9
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: Bio-Path Holdings, Inc.
Industry: Medical - Drugs
1Q22: Clinical Programs on Track, BP1003 Data at AACR, Cash Well Into 2023
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Bio-Path Holdings, Inc.
Industry: Medical - Drugs
Company: Bio-Path Holdings, Inc.
Industry: Medical - Drugs
Company: Bio-Path Holdings, Inc.
Industry: Medical - Drugs
BP1003 Enhances Taxol/5-FU Efficacy in Breast & Ovarian Cancer Cells
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Bio-Path Holdings, Inc.
Industry: Medical - Drugs
Company: Bio-Path Holdings, Inc.
Industry: Medical - Drugs
4Q21: Preclinical BP1003 Data at AACR, Funded Well Into 2023
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Bio-Path Holdings, Inc.
Industry: Medical - Drugs
Company: Bio-Path Holdings, Inc.
Industry: Medical - Drugs
Company: Bio-Path Holdings, Inc.
Industry: Medical - Drugs
ASH Poster Demonstrates Clear Utility of Prexigebersen in High Risk AML
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Bio-Path Holdings, Inc.
Industry: Medical - Drugs
Company: Bio-Path Holdings, Inc.
Industry: Medical - Drugs
Company: Bio-Path Holdings, Inc.
Industry: Medical - Drugs
3Q21: Two Recent IND Clearances Expand Clinical Programs, Funded Into 2023
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J